Abstract:Abstract Background and Aims: Hepatocellular carcinoma (HCC), a prevalent solid organ malignancy, is intricately linked to the glycolytic enzyme Alpha-enolase (ENO1). ENO1's overexpression is associated with malignant tumor progression and poor clinical outcomes, yet its role in HCC cell proliferation and differentiation warrants further investigation. This study focuses on identifying ENO1-interacting proteins in HCC, exploring their involvement in cell proliferation and the cell cycle. Materials and Methods: We employed RNA interference to downregulate ENO1 in HepG2 cells, evaluating effects on cell proliferation, cycle progression, and key signaling pathways using MTT assays, flow cytometry, and Western blotting. Identifying ENO1-interacting proteins involved combining RNAi and co-immunoprecipitation with isobaric tags (iTRAQ). We confirmed five proteins central to proliferation and cell cycle regulation through immunofluorescence microscopy and additional co-immunoprecipitation. Pathway analysis and follow-up experiments were conducted for further elucidation. Results: ENO1 silencing significantly inhibited HepG2 cell proliferation and extended G2/M and S phases. We identified 40 ENO1-interacting proteins with notable expression changes, including PCNA, HSP90, PCBP1, PSME1, and PEBP1. Significant downregulation was observed in PCNA, various cyclins, and phosphorylated ERK1/2, MAPK, and AKT, alongside an upregulation of P21. However, levels of CDK1, CDK2, ERK1/2, MAPK, and AKT remained unchanged. Conclusions: This study highlights the glycolytic pathway's crucial role in HCC development. The identified ENO1-interacting proteins like PCNA, HSP90, PCBP1, PSME1, and PEBP1 are key in tumor development, differentiation, invasion, and metastasis. The interaction between ENO1 and PCNA, influencing cell cycle regulators and phosphorylation processes, offers new insights into HCC molecular dynamics and potential therapeutic avenues.

Mediation of PKM2-dependent glycolytic and non-glycolytic pathways by ENO2 in head and neck cancer development

ENO3 Promotes Colorectal Cancer Progression by Enhancing Cell Glycolysis

ENO1 and Cancer

ENO2 Promotes Colorectal Cancer Metastasis by Interacting with the LncRNA CYTOR and Activating YAP1-Induced EMT.

ENO2 Promotes Cell Proliferation, Glycolysis, and Glucocorticoid-Resistance in Acute Lymphoblastic Leukemia.

Overexpression of Enolase 2 is Associated with Worsened Prognosis and Increased Glycikolysis in Papillary Renal Cell Carcinoma

Role of ENO1 and its targeted therapy in tumors

Enolase 1, a Moonlighting Protein, as a Potential Target for Cancer Treatment

O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer.

Enolase 1 Stimulates Glycolysis to Promote Chemoresistance in Gastric Cancer.

Interference with ENO2 promotes ferroptosis and inhibits glycolysis in clear cell renal cell carcinoma by regulating Hippo‐YAP1 signaling

Exploring the Role of ENO1 in Regulating Cell Proliferation and Cell Cycle in Hepatocellular Carcinoma: Insights from Proteomic Analysis

Tumor-derived Exosomal ENO2 Modulates Polarization of Tumor-associated Macrophages through Reprogramming Glycolysis to Promote Progression of Diffuse Large B-cell Lymphoma

Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway

The Moonlighting Function of Glycolytic Enzyme Enolase-1 Promotes Choline Phospholipid Metabolism and Tumor Cell Proliferation

Engrailed 2 triggers the activation of multiple phosphorylation-induced signaling pathways in both transcription-dependent and -independent manners

ENO2-derived Phosphoenolpyruvate Functions As an Endogenous Inhibitor of HDAC1 and Confers Resistance to Antiangiogenic Therapy

An Enolase Inhibitor for the Targeted Treatment of ENO1-deleted Cancers

Enolase-1 is A Therapeutic Target in Endometrial Carcinoma

ENO1 Binds to ApoC3 and Impairs the Proliferation of T Cells via IL-8/STAT3 Pathway in OSCC

Enolase-phosphatase 1 Acts As an Oncogenic Driver in Glioma.